By Kennedy Ferruggia – Pharmacy Times –
The FDA has granted regenerative medicine advanced therapy (RMAT) designation for AIC100 (Affylmmune Therapeutics), an ICAM-1 targeting and affinity-tuned LFA-1 binder chimeric antigen receptor (CAR) T-cell therapy product candidate, for the treatment of recurrent anaplastic thyroid cancer (ATC).1 This form of thyroid cancer is reported to be a rare and highly aggressive malignant tumor that impacts 2% to 3% of all thyroid gland neoplasms. Study authors noted that ATC remains as the deadliest disease worldwide with few effective treatment options, with a median survival rate of less than 6 months.
